Treatment of breast cancer

摘要

Patients with aggressive breast cancer, including patients with estrogen receptor (ER) negative tumors and/or patients who have a disease-free interval from diagnosis to metastatic relapse of less than 36 months, have greater survival times than by treatment with DPPE and doxorubicin than patients receiving doxorubicin alone. Greater survival times are also achieved in patients receiving more than four cycles of treatment with DPPE and doxorubicin rather than doxorubicin alone. Greater survival times by treatment with DPPE and doxorubicin as compared to doxorubicin alone are further obtained in patients with metastatic breast cancer and who either have had no prior chemotherapy or no prior treatment type.